Characteristics and Outcomes of a Series of COVID-Associated Mucormycosis Patients in Two Different Settings in Egypt Through the Third Pandemic Wave

Figures & data

Table 1 Demographic Data of the Analyzed CAM Cases Grouped by Setting

Variable	Metropolitan Cairo (n = 15)	Upper Egypt (n = 11)	Total (n = 26)
Age (years)
Median (IQR)	58 (45–70)	64 (60–71)	62.5 (46–70)
Range	21–76	26–77	21–77
Gender
Males	8 (53.3%)	6 (54.5%)	14 (53.8%)
Females	7 (46.7%)	5 (45.5%)	12 (46.2%)

Abbreviation: IQR, interquartile range.

Table 2 Distribution of COVID-19-Related Variables Across the Studied Series (n = 26), Grouped by Setting

Variable	Metropolitan Cairo (n = 15)	Upper Egypt (n = 11)	Total (n = 26)
COVID-19 Severity
Mild	1 (6.7%)	5 (45.4%)	6 (23.1%)
Moderate	6 (40%)	2 (18.2%)	8 (30.7%)
Severe	8 (53.3%)	4 (36.4%)	12 (46.2%)
Treatment Setting
Home	2 (13.3%)	10 (90.9%)	12 (46.2%)
Hospital	13 (86.7%)	1 (9.1%)	14 (53.8%)
Corticosteroids Received
Yes	12 (80%)	8 (72.7%)	20 (76.9%)
No	3 (20%)	3 (27.3%)	6 (23.1%)
Tocilizumab Received
Yes	5 (33.3%)	0 (0%)	5 (19.2%)
No	10 (66.7%)	11 (100)	21 (80.8%)

Abbreviation: COVID-19, coronavirus disease 2019.

Table 3 CAM Presentation, Management, and Outcomes, Grouped by Setting

Variable	Metropolitan Cairo (n = 15)	Upper Egypt (n = 11)	Total (n = 26)
Onset
Coexisting with COVID-19	8 (53.3%)	7 (63.6%)	15 (57.7%)
After recovery from COVID-19	7 (46.7%)	4 (36.4%)	11 (42.3%)
Interval: COVID-19 to CAM (days)
Median (IQR)	30 (20–60)	15 (15–30)	20.5 (15–30)
Initial complaint
Facial Swelling	10 (66.7%)	3 (27.3%)	13 (50%)
Lid Swelling	3 (20%)	4 (36.3%)	7 (26.9%)
Skin blackish discoloration	2 (13.3%)	1 (9.1%)	3 (11.5%)
Nasal Obstruction	0 (0%)	2 (18.2%)	2 (7.7%)
Diminution of vision	0 (0%)	1 (9.1%)	1 (3.9%)
CDVA on presentation
20/40 (0.5) or better	3 (20%)	0 (0%)	3 (11.5%)
20/200 (0.1) - 20/40 (0.5)	0 (0%)	1 (9.1%)	1 (3.9%)
Fair on bedside assessment	3 (20%)	0 (0%)	3 (11.5%)
Light Perception	3 (20%)	0 (0%)	3 (11.5%)
No Light Perception (Lost)	6 (40%)	10 (90.9%)	16 (61.6%)
Surgical intervention
Yes	7 (46.7%)	10 (90.9%)	17 (65.4%)
No	8 (53.3%)	1 (9.1%)	9 (34.6%)
Final outcome
Recovery and Discharge	9 (60%)	5 (45.5%)	14 (53.8%)
Death	6 (40%)	6 (54.5%)	12 (46.2%)

Abbreviations: COVID-19, coronavirus disease 2019; CAM, COVID-associated mucormycosis; IQR, interquartile range; CDVA, corrected distance visual acuity.